TNF binding proteinAlternative Names: Recombinant tumour necrosis factor binding protein; rTNFbp; TNFbp
Latest Information Update: 20 Mar 1997
At a glance
- Originator Amgen
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 20 Mar 1997 Discontinued-II for Rheumatoid arthritis in USA (Unknown route)
- 15 Aug 1996 Phase-II clinical trials for Rheumatoid arthritis in USA (Unknown route)
- 28 Jun 1996 New profile